Recap: Biomarin Pharmaceutical Q4 Earnings - Biomarin Pharmaceutical (NASDAQ:BMRN)

Biomarin Pharmaceutical BMRN reported its Q4 earnings results on Thursday, February 22, 2024 at 04:05 PM.

Here's what investors need to know about the announcement.

Biomarin Pharmaceutical beat estimated earnings by 113.04%, reporting an EPS of $0.49 versus an estimate of $0.23.

Revenue was up $108.67 million from the same period last year.

Last quarter the company beat on EPS by $0.24 which was followed by a 5.17% drop in the share price the next day.

Here's a look at Biomarin Pharmaceutical's past performance:

Quarter	Q3 2023	Q2 2023	Q1 2023	Q4 2022
EPS Estimate	0.22	0.47	0.18	-0.07
EPS Actual	0.46	0.54	0.60	0
Revenue Estimate	608.33M	591.46M	570.62M	536.97M
Revenue Actual	581.33M	595.27M	596.41M	537.54M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Biomarin Pharmaceutical management provided guidance for FY 2024, expecting earnings between $2.6 and $2.8 per share.

To track all earnings releases for Biomarin Pharmaceutical visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.